Cervical Cancer Diagnostics And Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 5.44 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cervical Cancer Diagnostics And Therapeutics Market Analysis
The Global Cervical Cancer Diagnostics And Therapeutics Market is expected to register a CAGR of 7.80% during the forecast period.
Favorable government initiatives, such as funding for cervical cancer prevention programs and vaccination drives, a rising prevalence of cervical cancer due to factors like HPV infection, heightened awareness of early diagnosis through public health campaigns, and robust R&D efforts by key players in developing advanced diagnostic tools and effective drugs, are driving the growth of the cervical cancer diagnostics and therapeutics market.
The increasing awareness of cervical cancer and its treatment is expected to increase the adoption of cervical cancer drugs and diagnostics devices, thereby boosting the market's growth. For instance, in May 2022, the National Health Mission (NHM) and the Clinton Health Access Initiative collaborated to introduce a training program in Uttar Pradesh, India. The initiative aims to equip gynecologists and nurses with the skills to identify cervical cancer cases in their nascent stages. Such governmental initiatives aid in the early diagnosis and treatment of cervical cancer and bolster the market's growth.
The market has experienced significant growth, driven by the rising global incidence of cervical cancer among women. As per BGI Genomics Releases 2023 Global Report on Cervical Cancer Awareness, cervical cancer ranks as the fourth most prevalent cancer in women worldwide, with approximately 604,000 new cases reported in 2023. Thus, increasing adoption of cervical cancer diagnostic tests for early disease detection is poised to propel the market's growth during the forecast period.
Moreover, the introduction of enhanced combination drugs and diagnostic tests is poised to drive growth in the cervical cancer diagnostics and therapeutics market. For instance, in September 2022, the Drugs Controller General of India (DCGI) granted market authorization to the Serum Institute of India (SII) to manufacture an indigenously developed vaccine against cervical cancer. Similarly, in June 2022, Karkinos Healthcare, an oncology-focused health-tech platform, launched CerviRaksha, a first-of-its-kind clinically validated HPV test that is prequalified by the World Health Organization and approved by the Food and Drug Administration in partnership with the Karkinos network hospital doctors and nurses. Such drug approval increases access to this treatment, propelling the market's growth during the forecast period.
Therefore, growing awareness initiatives, the high prevalence of cervical cancer, and drug launches are expected to contribute to the market growth over the projected period. However, in many countries, irregular testing due to financial constraints and the exorbitant costs of cancer treatments hampers market expansion.
Cervical Cancer Diagnostics And Therapeutics Market Trends
The HPV Test Segment is Expected to Hold a Major Market Share During the Forecast Period
The Papanicolaou test is a cervical screening method that detects precancerous and cancerous processes in the cervix and colon. Abnormal findings are frequently followed by more sensitive diagnostic procedures and, if necessary, interventions aimed at preventing cervical cancer progression. An HPV test is recommended for women over 30 to detect the virus. The screening aids in detecting precancerous lesions caused by HPV, which can then be removed to prevent the development of invasive cancers.
The major factor driving the segment's growth includes the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the Globocan 2022, there were 662 thousand cases of cervical cancer reported across the world in 2022, and this number is projected to increase by 909 thousand by 2024. Therefore, the incidence of cervical cancer is found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes in the cervix years before the cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.
Moreover, increasing product launches in the country boosts the market. For instance, in May 2024, Roche secured FDA approval for its human papillomavirus (HPV) self-collection solution, marking a pioneering entry into the US market. HPV screening plays a crucial role in pinpointing women vulnerable to cervical cancer, enabling early detection and intervention, thereby mitigating the risk of cervical cancer development.
Thus, all the aforementioned factors, such as the growing burden of cervical cancer and the launches of HPV tests, are anticipated to drive the segment's growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is one of the largest cervical cancer diagnostics and therapeutics markets. The large market share is attributed to the high awareness of disease prevention among women in the region and to the many initiatives launched to prevent cervical cancer that have increased the reach of insurance coverage for cervical screening tests, especially for low-income women.
Cervical cancer is one of the leading causes of death among women in the United States. According to the American Cancer Society, based on data updated in January 2024 and the estimates for cervical cancer in the United States for 2022, about 13,820 new cases of invasive cervical cancer will be diagnosed. Since there are more cases of cervical cancer in the United States, the market is likely to grow quickly over the next few years.
Additionally, favorable government policies in the United States are expected to drive the market during the forecast period. Updates from the Centers for Disease Control and Prevention in February 2022 reported that the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for screening for breast and cervical cancer has helped the market grow in the United States. Additionally, the month of January has been designated "Cervical Health Awareness Month" by the US Congress. The National Cervical Cancer Coalition (NCCC) and its many local chapters across the country raise awareness about cervical cancer, HPV disease, and the importance of early detection during January. While NCCC chapters host events throughout the year, Cervical Health Awareness Month is observed in January, and chapters work to raise awareness in their communities.
Moreover, growing product launches by the key market players support the market's growth. For instance, in July 2023, Merck revealed that in the Phase 3 KEYNOTE-A18 trial (ENGOT-cx11/GOG-3047), KEYTRUDA, its anti-PD-1 therapy, combined with external beam radiotherapy (EBRT) and concurrent chemotherapy, succeeded in meeting a primary endpoint: progression-free survival (PFS). This treatment was administered to newly diagnosed patients grappling with high-risk locally advanced cervical cancer.
Thus, all aforementioned factors, such as the growing burden of cervical cancer and product launches, are expected to grow in the coming years in North America.
Cervical Cancer Diagnostics and Therapeutics Industry Overview
The cervical cancer diagnostics and therapeutics market is semi-consolidated and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology. Some of the major companies in the market are Abbott Laboratories, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Qiagen NV, Advaxis Inc., Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd.
Cervical Cancer Diagnostics and Therapeutics Market Leaders
-
Novartis AG
-
Becton, Dickinson and Company
-
Abbott Laboratories
-
F. Hoffman-La Roche Ltd
-
GlaxoSmithKline Plc
*Disclaimer: Major Players sorted in no particular order
Cervical Cancer Diagnostics and Therapeutics Market News
- April 2024: Genmab AS and Pfizer Inc. disclosed that the United States Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for TIVDAK (tisotumab vedotin-tftv). This approval is specifically for treating patients diagnosed with recurrent or metastatic cervical cancer whose disease has advanced post-chemotherapy.
- January 2024: BD (Becton, Dickinson and Company) and Techcyte, a prominent player in AI-driven digital diagnostics, entered a strategic collaboration. Their goal is to introduce an AI algorithm. This algorithm is designed to assist cytologists and pathologists in the swift and accurate detection of cervical cancer and precancerous signs, leveraging whole-slide imaging technology.
Cervical Cancer Diagnostics and Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Favorable Government Initiatives toward Cervical Cancer Prevention
4.2.2 Increasing Prevalence of Cervical Cancer and Increasing Awareness Regarding Early Diagnosis
4.2.3 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
4.3 Market Restraints
4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Diagnostic Test
5.1.1 Pap Smear Test
5.1.2 HPV Test
5.1.3 Colposcopy
5.1.4 Biopsy and Endocervical Curettage
5.1.5 Other Diagnostic Tests
5.2 By Therapeutics
5.2.1 Avastin (Bevacizumab)
5.2.2 Blenoxane (Bleomycin)
5.2.3 Hycamtin (Topotecan Hydrochloride)
5.2.4 Gemcitabine-Cisplatin
5.2.5 Vaccines
5.2.5.1 Gardasil
5.2.5.2 Cevarix
5.2.6 Other Therapeutics
5.3 By End User
5.3.1 Hospitals
5.3.2 Specilty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.3.4 Diagnostic Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bristol-Myers Squibb Company
6.1.3 GlaxoSmithKline PLC
6.1.4 Merck & Co. Inc.
6.1.5 Pfizer Inc.
6.1.6 Qiagen NV
6.1.7 Advaxis Inc.
6.1.8 Becton, Dickinson and Company
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 DYSIS Medical Ltd
6.1.11 The Cooper Companies Inc.
6.1.12 Arbor Vita Corporation
6.1.13 Zilico Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cervical Cancer Diagnostics And Therapeutics Industry Segmentation
Cervical cancer refers to a malignancy of cervical cells. More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The two most common types of cervical cell cancer are squamous cell malignancy and adenocarcinoma. Cervical cancer diagnostic tests are being widely used for the detection of precancerous or cancerous lesions in the cervix of females.
The cervical cancer diagnostics and therapeutics market has been segmented by diagnostic test, therapeutics, end users, and geography. By diagnostics test, the market is segmented into pap smear test, HPV test, colposcopy, biopsy and endocervical curettage, and other diagnostic tests. By therapeutics, the market is segmented as avastin (bevacizumab), blenoxane (bleomycin), hycamtin (topotecan hydrochloride), gemcitabine-cisplatin, vaccines, and other therapeutics. By end user, the market is segmented as hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report provides value in USD for the aforementioned segments.
| By Diagnostic Test | |
| Pap Smear Test | |
| HPV Test | |
| Colposcopy | |
| Biopsy and Endocervical Curettage | |
| Other Diagnostic Tests |
| By Therapeutics | ||||
| Avastin (Bevacizumab) | ||||
| Blenoxane (Bleomycin) | ||||
| Hycamtin (Topotecan Hydrochloride) | ||||
| Gemcitabine-Cisplatin | ||||
| ||||
| Other Therapeutics |
| By End User | |
| Hospitals | |
| Specilty Clinics | |
| Cancer and Radiation Therapy Centers | |
| Diagnostic Centers |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cervical Cancer Diagnostics and Therapeutics Market Research FAQs
What is the current Global Cervical Cancer Diagnostics And Therapeutics Market size?
The Global Cervical Cancer Diagnostics And Therapeutics Market is projected to register a CAGR of 5.44% during the forecast period (2024-2029)
Who are the key players in Global Cervical Cancer Diagnostics And Therapeutics Market?
Novartis AG, Becton, Dickinson and Company, Abbott Laboratories, F. Hoffman-La Roche Ltd and GlaxoSmithKline Plc are the major companies operating in the Global Cervical Cancer Diagnostics And Therapeutics Market.
Which is the fastest growing region in Global Cervical Cancer Diagnostics And Therapeutics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Cervical Cancer Diagnostics And Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Cervical Cancer Diagnostics And Therapeutics Market.
What years does this Global Cervical Cancer Diagnostics And Therapeutics Market cover?
The report covers the Global Cervical Cancer Diagnostics And Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Cervical Cancer Diagnostics And Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cervical Cancer Treatment Industry Report
Statistics for the 2024 Cervical Cancer Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cervical Cancer Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
